A phase 3 pivotal study of REOLYSIN in in combination with paclitaxel, for the treatment HR+/HER2- metastatic breast cancer patients.

Trial Profile

A phase 3 pivotal study of REOLYSIN in in combination with paclitaxel, for the treatment HR+/HER2- metastatic breast cancer patients.

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Pelareorep (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 09 Mar 2018 According to an Oncolytics Biotech media release, company expects to initiate this study in combination with paclitaxel in Q32018.
    • 16 Feb 2018 New trial record
    • 14 Feb 2018 According to an Oncolytics Biotech media release, this registrational trial is expected to start before the end of September 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top